Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC

This study is an open label, single arm, multicenter clinical trial. The aim of this study is to evaluate the efficacy, safety, and quality of life of radiotherapy combined with Fuzuloparib and Abiraterone Acetate Tablets(Ⅱ) as first-line treatment for castration resistant prostate cancer patients. The study aims to enroll 40 eligible subjects with PSA response rate (PSA 50) as the primary endpoint.

Trial Details

NCT ID
NCT06971211
Phase
PHASE2
Sponsor
Jianbin Bi
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone.
Locations (sample)
  • Shenyang, Liaoning, China|41.79222,123.43278

Key Eligibility Criteria

  • Age ≥ 18 years old, male
  • ECOG score is 0 or 1
  • Untreated first-line metastatic castration resistant prostate cancer patients
  • Allow the use of a new endocrine drug treatment once during hormone sensitive stages

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →